Medicines Co. Aktie
-
Deine Einschätzung
Was spricht für und gegen Medicines Co. in den nächsten Jahren?
Pro
Kontra
Rendite von Medicines Co. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | -0,44 % | 3,13 % | 16,43 % | 13,86 % | -12,21 % | -4,59 % | -28,34 % |
| Opko Health Inc. | 4,76 % | 3,13 % | 10,00 % | 23,41 % | 21,08 % | -27,99 % | -59,87 % |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 4,29 % | 6,92 % | 3,03 % | -9,57 % | -13,27 % | -35,11 % | -31,45 % |
Kommentare
News
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines (NASDAQ: RVMD) spent most of its history as a publicly traded company -- that's since 2020 -- trading for less than $50 a share. The company offers a new approach to oncology
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Most clinical-stage biotechs are small-cap companies. That makes sense. Not only can it take years -- sometimes over a decade -- to develop novel medicines, but it is also a very risky endeavor
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
The June 10 IPO of Parabilis Medicines (NASDAQ: PBLS) closed up 58% from its $20 offer price. Two days later, Space Exploration Technologies, the largest IPO in history, finished its debut up just




